ffxssj
It's certainly true that the market cap model is precedent on commercialisation, which is why I initially stated a proven products and revenue stream. The proof, as they say, will be in the pudding once stable sales/earnings are established. as you rightly say, a few quarterlies down the track.
No question, the P/E ratios applied now are significantly less than pre-GFC, however back then the norm for Bio-meds was 18-20 times forward earnings. Now we are seeing roughly 10-16 times.
There are also options available for the funding of the commercialisation of Cvac, th the form of fresh equity, debt, a combination of the two or even forward roylaty payments from drug marketing partners.
Nothing is guaranteed but many things are possible.
ffxssjIt's certainly true that the market cap model is precedent...
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $490.2M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 33.5¢ | $586.8K | 1.727M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 41904 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 312733 | 22 |
View Market Depth
| Last trade - 15.28pm 31/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |